Core Viewpoint - Anxu Bio announced that its major shareholder, Ma Huaxiang, plans to reduce his stake in the company due to personal financial needs, with a potential sale of up to 1.2 million shares, representing 0.94% of the total share capital, between December 11, 2025, and March 10, 2026 [1] Summary by Categories - **Shareholder Actions** - Ma Huaxiang, a shareholder holding more than 5% of the company, intends to sell up to 1.2 million shares [1] - The reduction in shares will occur through centralized bidding transactions [1] - **Timeline and Conditions** - The planned reduction period is set from December 11, 2025, to March 10, 2026 [1] - The selling price will be determined based on market conditions [1] - The implementation of this reduction plan carries uncertainties [1]

Core Viewpoint - Anxu Bio (688075.SH) announced that shareholder Ma Huaxiang plans to reduce his holdings by up to 1.2 million shares, representing no more than 0.94% of the company's total share capital due to personal funding needs [1] Summary by Relevant Categories - **Shareholder Actions** - Shareholder Ma Huaxiang intends to reduce his stake in the company through centralized bidding transactions [1] - The total number of shares to be reduced is capped at 1.2 million [1] - **Impact on Company** - The reduction represents a maximum of 0.94% of the company's total share capital [1]

Core Viewpoint - Anxu Bio (688075.SH) announced that shareholder Ma Huaxiang plans to reduce his holdings by up to 1.2 million shares, representing no more than 0.94% of the company's total share capital due to personal funding needs [1] Summary by Category - **Company Actions** - Ma Huaxiang intends to reduce his shareholding through centralized bidding transactions [1] - The total number of shares to be sold is capped at 1.2 million [1] - **Shareholder Information** - The reduction in shareholding is attributed to Ma Huaxiang's personal financial requirements [1] - The percentage of total share capital affected by this reduction is 0.94% [1]

Group 1 - The core point of the announcement is that shareholder Ma Huaxiang plans to reduce his stake in Anxu Bio by up to 120,000 shares, which is approximately 0.94% of the total share capital, due to personal financial needs [1] - As of the announcement date, Ma Huaxiang holds about 14.77 million shares, representing 11.62% of the total share capital of Anxu Bio [1] - The shares to be sold were acquired before the company's initial public offering and will be tradable starting from November 18, 2024 [1] Group 2 - Anxu Bio's revenue for the year 2024 is expected to be entirely derived from the in vitro diagnostic industry, accounting for 100% of its revenue [1] - The current market capitalization of Anxu Bio is 5.3 billion yuan [2]

证券代码：688075 证券简称：安旭生物 公告编号：2025-032 杭州安旭生物科技股份有限公司 股东减持股份计划公告 本次减持期间，通过集中竞价方式减持的，自公告披露之日起 15 个交易日 后的 3 个月内进行。 减持价格按市场价格确定，若在上述减持计划期间，公司发生派发红利、送 红股、转增股本、增发新股或配股等股本除权、除息事项的，则上述减持计划将 作相应调整。 公司于 2025 年 11 月 18 日收到股东马华祥出具的《关于股份减持计划的告 知函》。现将相关减持计划情况公告如下 | 股东名称 | 马华祥 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，马华祥持有杭州安旭生物科技股份有限公司（以下简称 "公司"）股份 14,773,360 股，占公司总股本的 ...

Core Viewpoint - Anxu Bio (688075) announced that its shareholder, Ma Huaxiang, who holds 11.62% of the company's shares, plans to reduce his holdings by up to 1.2 million shares, representing no more than 0.94% of the total share capital of the company, through centralized bidding transactions [1] Summary by Categories - Shareholder Reduction Plan - Ma Huaxiang intends to reduce his shareholding by up to 1.2 million shares [1] - The reduction will not exceed 0.94% of the company's total share capital [1] - The total number of shares reduced within any consecutive 90 natural days will not exceed 1% of the company's total shares [1]

Core Viewpoint - Anxu Bio (688075.SH) announced that shareholder Ma Huaxiang plans to reduce his stake in the company due to personal funding needs, with a maximum reduction of 1.2 million shares, representing 0.94% of the total share capital [1] Summary by Sections - **Shareholder Reduction Plan** - Ma Huaxiang intends to reduce his holdings through centralized bidding, with the total number of shares reduced not exceeding 1.2 million [1] - The reduction will not exceed 1.00% of the company's total shares within any consecutive 90-day period [1] - **Timing and Pricing** - The reduction period will commence 15 trading days after the announcement and will last for three months [1] - The selling price will be determined based on market conditions [1]

格隆汇11月18日｜安旭生物公告，马华祥持股1477.34万股，占总股本11.62%，拟自公告披露之日起15 个交易日后的3个月内，通过集中竞价减持不超过120万股，不超总股本0.94%，且任意连续90个自然日 内减持不超1.00%。 ...

安旭生物公告，马华祥持股1477.34万股，占总股本11.62%，拟自公告披露之日起15个交易日后的3个月 内，通过集中竞价减持不超过120万股，不超总股本0.94%，且任意连续90个自然日内减持不超1.00%。 ...

杭州安旭生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 25 日（星期二）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 证券代码：688075 证券简称：安旭生物 公告编号：2025-031 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 18 日（星期二）至 11 月 24 日（星期一）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jun.yu@diareagent.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 杭州安旭生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便 ...